Apellis Pharmaceuticals, Inc. (the "Company") elected Mikael Dolsten, M.D., Ph.D., to its Board of Directors as a Class I director. The appointment is effective as of March 1, 2026, and Dr. Dolsten will serve until the Annual Meeting of Stockholders in 2027 or until his successor is duly elected. The Board determined that Dr. Dolsten is independent as contemplated by Nasdaq Stock Market rules. Dr. Dolsten will be compensated in the same manner as other non-employee directors. His compensation includes an option to purchase common stock with a Black-Scholes valuation of $300,000, vesting one-third on each of the first, second, and third anniversaries of the grant date. He also received Restricted Stock Units (RSUs) for shares valued at $300,000, which will vest in full on the first anniversary of the grant date, with an option to defer vesting. Vesting of both the option and RSUs will accelerate in full upon a change in control of the Company. There are no arrangements or understandings for his election, no family relationships with other directors or executive officers, and no disclosable related party transactions. Dr. Dolsten has entered into an indemnification agreement with the Company.